Surgical management of brainstem hemangioblastomas in patients with von Hippel—Lindau disease
- 1 January 2003
- journal article
- case report
- Published by Journal of Neurosurgery Publishing Group (JNSPG) in Journal of Neurosurgery
- Vol. 98 (1), 95-105
- https://doi.org/10.3171/jns.2003.98.1.0095
Abstract
Object. Hemangioblastomas of the brainstem constitute 5 to 10% of central nervous system (CNS) tumors in patients with von Hippel—Lindau (VHL) disease. At present, optimal management of brainstem hemangioblastomas associated with VHL disease is incompletely defined. In an attempt to clarify some of the uncertainty about the operative treatment of these lesions and its outcome, the authors reviewed all cases of VHL disease in which resection of brainstem hemangioblastomas was performed at the National Institutes of Health during a 10-year period. Methods. Twelve consecutive patients with VHL disease (six male and six female patients [mean age 31.7 ± 9 years; range 15–46 years]) who underwent 13 operations to remove 17 brainstem hemangioblastomas were included in this study (mean follow-up period, 88.4 ± 37.4 months; range 37–144 months). Serial examinations, hospital charts, magnetic resonance images, and operative records were reviewed. To evaluate clinical course, clinical grades were assigned to each patient before and after surgery. Preoperative neurological function was the best predictor of long-term outcome. In addition, patients who underwent CNS surgeries for hemangioblastomas were more likely to improve or to remain neurologically stable. Tumor or cyst size, the presence of a cyst, or the location of the tumor (intramedullary, extramedullary, or mixed; posterior medullary, obex, or lateral) did not affect outcome. No patient was neurologically worse after brainstem surgery. At long-term follow-up review (mean 88.4 months), only one patient had declined neurologically and this was due to the cumulative neurological effects caused by eight additional hemangioblastomas of the spinal cord and their surgical treatment. Conclusions. Brainstem hemangioblastomas in patients with VHL disease can be removed safely; they generally should be resected when they become symptomatic or when the tumor has reached a size such that further growth will increase the risks associated with surgery, or in the presence of an enlarging cyst. Magnetic resonance imaging is usually sufficient for preoperative evaluation and presurgical embolization is unnecessary. The goal of surgery is complete resection of the lesion before the patient experiences a disabling neurological deficit.Keywords
This publication has 42 references indexed in Scilit:
- Germline mutations in the von Hippel-Lindau disease tumor suppressor gene: Correlations with phenotypeHuman Mutation, 1995
- Endovascular embolization and surgical excision for the treatment of cerebellar and brain stem hemangioblastomasSurgical Neurology, 1994
- Identification of the von Hippel-Lindau Disease Tumor Suppressor GeneScience, 1993
- Volume of Pituitary MacroadenomasJournal of Computer Assisted Tomography, 1992
- Localization of the von Hippel-Lindau disease gene to a small region of chromosome 3Genomics, 1990
- Intramedullary ependymoma of the spinal cordJournal of Neurosurgery, 1990
- Von Hippel–Lindau disease maps to the region of chromosome 3 associated with renal cell carcinomaNature, 1988
- Posterior fossa hemangioblastomasSurgical Neurology, 1986
- Successful removal of a brainstem hemangioblastomaSurgical Neurology, 1986
- Surgical treatment of vascular lesions in the brain stemJournal of Neurosurgery, 1975